MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Charles River Laboratories International Inc

Geschlossen

BrancheGesundheitswesen

154.22 -2.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

153.42

Max

158.98

Schlüsselkennzahlen

By Trading Economics

Einkommen

240M

26M

Verkäufe

-18M

984M

KGV

Branchendurchschnitt

592.3

39.564

Gewinnspanne

2.629

Angestellte

18,700

EBITDA

271M

184M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-1.68% downside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-159M

7.7B

Vorheriger Eröffnungskurs

156.7

Vorheriger Schlusskurs

154.22

Nachrichtenstimmung

By Acuity

11%

89%

7 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juli 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15. Juli 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15. Juli 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15. Juli 2025, 20:07 UTC

Ergebnisse

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15. Juli 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15. Juli 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15. Juli 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15. Juli 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15. Juli 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15. Juli 2025, 18:32 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15. Juli 2025, 18:31 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15. Juli 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15. Juli 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15. Juli 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

-1.68% Nachteil

12-Monats-Prognose

Durchschnitt 156.73 USD  -1.68%

Hoch 182 USD

Tief 100 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

5

Buy

8

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

7 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.